Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA 98109-1023, USA.
Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109-1023, USA.
Future Oncol. 2023 Feb;19(5):369-383. doi: 10.2217/fon-2022-0767. Epub 2023 Mar 6.
Investigate oncologist and patient preferences for the first-line treatment of advanced urothelial carcinoma. A discrete-choice experiment was used to elicit treatment attribute preferences, including patient treatment experience (number and duration of treatments and grade 3/4 treatment-related adverse events), overall survival and treatment administration frequency. The study included 151 eligible medical oncologists and 150 patients with urothelial carcinoma. Both physicians and patients appeared to prefer treatment attributes related to overall survival, treatment-related adverse events and the number and duration of the medications in a regimen over frequency of administration. Overall survival had the most influence in driving oncologists' treatment preferences, followed by the patient's treatment experience. Patients found the treatment experience the most important attribute when considering options, followed by overall survival. Patient preferences were based on treatment experience, while oncologists preferred treatments that prolong overall survival. These results help to direct clinical conversations, treatment recommendations and clinical guideline development.
调查肿瘤学家和患者对晚期尿路上皮癌一线治疗的偏好。采用离散选择实验来引出治疗属性偏好，包括患者的治疗体验（治疗次数和持续时间以及 3/4 级与治疗相关的不良事件）、总生存期和治疗给药频率。该研究纳入了 151 名合格的肿瘤学家和 150 名尿路上皮癌患者。医生和患者似乎都更倾向于与总生存期、治疗相关的不良事件以及方案中药物的数量和持续时间相关的治疗属性，而不是给药频率。总生存期对驱动肿瘤学家治疗偏好的影响最大，其次是患者的治疗体验。在考虑选择时，患者认为治疗体验是最重要的属性，其次是总生存期。患者的偏好基于治疗体验，而肿瘤学家则更倾向于延长总生存期的治疗方法。这些结果有助于指导临床对话、治疗建议和临床指南的制定。
